The BCR-ABL inhibitor nilotinib influences phenotype and function of monocyte-derived human dendritic cells

No abstract is available for this paper.

• Publication year

  2018

• Venue

  Cancer Immunology and Immunotherapy

• Publication date

  2018-02-21

• Fields of study

  Biology, Medicine, Chemistry

• Identifiers
  DOI 10.1007/s00262-018-2129-9PMID 29468363PMCID PMC11028318
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Discontinuation of dasatinib or nilotinib in chronic myeloid leukemia: interim analysis of the STOP 2G-TKI study.

  2017cited by this paper
• Nilotinib-induced vasculopathy: identification of vascular endothelial cells as a primary target site

  2017cited by this paper
• Long-Term Follow-Up of the French Stop Imatinib (STIM1) Study in Patients With Chronic Myeloid Leukemia.

  2017cited by this paper
• Immunological off-target effects of imatinib

  2016cited by this paper
• Optimized chemical proteomics assay for kinase inhibitor profiling.

  2015cited by this paper
• Safety and efficacy of imatinib cessation for CML patients with stable undetectable minimal residual disease: results from the TWISTER study.

  2013cited by this paper
• Phase I clinical trial combining imatinib mesylate and IL-2 in refractory cancer patients

  2013cited by this paper
• Imatinib mesylate and nilotinib affect MHC-class I presentation by modulating the proteasomal processing of antigenic peptides

  2012cited by this paper
• The immune inhibitory receptor osteoactivin is upregulated in monocyte-derived dendritic cells by BCR–ABL tyrosine kinase inhibitors

  2012cited by this paper
• Leukemic stem cell persistence in chronic myeloid leukemia patients with sustained undetectable molecular residual disease.

  2011cited by this paper
• Effects of BCR-ABL inhibitors on anti-tumor immunity.

  2011cited by this paper
• Patients with chronic myeloid leukemia who maintain a complete molecular response after stopping imatinib treatment have evidence of persistent leukemia by DNA PCR

  2010cited by this paper
• Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial.

  2010cited by this paper
• Dasatinib versus Imatinib in Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia

  2010cited by this paper
• The BCR/ABL‐inhibitors imatinib, nilotinib and dasatinib differentially affect NK cell reactivity

  2010cited by this paper
• Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia.

  2010cited by this paper
• Nilotinib versus Imatinib for Newly Diagnosed Chronic Myeloid Leukemia

  2010cited by this paper
• Sipuleucel-T immunotherapy for castration-resistant prostate cancer.

  2010cited by this paper
• Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia.

  2010cited by this paper
• Inflammatory cytokines as a third signal for T cell activation.

  2010cited by this paper
• BCR/ABL Inhibitors Influence Phenotype and Function of Monocyte-Derived Human Dendritic Cells.

  2009cited by this paper
• Integrated data from 2 randomized, double‐blind, placebo‐controlled, phase 3 trials of active cellular immunotherapy with sipuleucel‐T in advanced prostate cancer

  2009cited by this paper
• Expression of stromal-cell-derived factor-1 on circulating platelets is increased in patients with acute coronary syndrome and correlates with the number of CD34+ progenitor cells.

  2009cited by this paper
• Imatinib mesylate and nilotinib affect MHC-class I presentation by modulating the proteasomal processing of antigenic peptides

  2009cited by this paper
• Dasatinib inhibits recombinant viral antigen-specific murine CD4+ and CD8+ T-cell responses and NK-cell cytolytic activity in vitro and in vivo.

  2009cited by this paper
• Positive Impact of T-Cell Clonal Expansion On Overall Survival in Patients with High-Risk Myelodysplastic Syndromes.

  2009cited by this paper
• Dasatinib, a small-molecule protein tyrosine kinase inhibitor, inhibits T-cell activation and proliferation.

  2008cited by this paper
• Profound Inhibition of Antigen-Specific T-Cell Effector Functions by Dasatinib

  2008cited by this paper
• Dasatinib exerts an immunosuppressive effect on CD8+ T cells specific for viral and leukemia antigens.

  2008cited by this paper
• Chemical proteomic profiles of the BCR-ABL inhibitors imatinib, nilotinib, and dasatinib reveal novel kinase and nonkinase targets.

  2007cited by this paper
• Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia.

  2006cited by this paper
• Placebo-controlled phase III trial of immunologic therapy with sipuleucel-T (APC8015) in patients with metastatic, asymptomatic hormone refractory prostate cancer.

  2006cited by this paper
• Imatinib mesylate minimally affects bcr‐abl+ and normal monocyte‐derived dendritic cells but strongly inhibits T cell expansion despite reciprocal dendritic cell‐T cell activation

  2006cited by this paper
• Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias.

  2006cited by this paper
• Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL.

  2006cited by this paper
• Effects of Imatinib on Monocyte-Derived Dendritic Cells Are Mediated by Inhibition of Nuclear Factor-κB and Akt Signaling Pathways

  2005cited by this paper
• Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl.

  2005cited by this paper
• Imatinib mesylate (STI-571) enhances antigen-presenting cell function and overcomes tumor-induced CD4+ T-cell tolerance.

  2005cited by this paper
• Imatinib mesylate affects the development and function of dendritic cells generated from CD34+ peripheral blood progenitor cells.

  2004cited by this paper
• Discovery of N-(2-chloro-6-methyl- phenyl)-2-(6-(4-(2-hydroxyethyl)- piperazin-1-yl)-2-methylpyrimidin-4- ylamino)thiazole-5-carboxamide (BMS-354825), a dual Src/Abl kinase inhibitor with potent antitumor activity in preclinical assays.

  2004cited by this paper
• Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia.

  2003cited by this paper
• Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia.

  2003cited by this paper
• Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia.

  2002cited by this paper
• Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia.

  2001cited by this paper
• Clinical Resistance to STI-571 Cancer Therapy Caused by BCR-ABL Gene Mutation or Amplification

  2001cited by this paper
• The epithelial tumor antigen MUC1 is expressed in hematological malignancies and is recognized by MUC1-specific cytotoxic T-lymphocytes.

  2001cited by this paper
• Immunobiology of dendritic cells.

  2000cited by this paper
• Immunotherapy of hormone-refractory prostate cancer with antigen-loaded dendritic cells.

  2000cited by this paper
• Dendritic cells and the control of immunity

  1998cited by this paper
• Generation of functional human dendritic cells from adherent peripheral blood monocytes by CD40 ligation in the absence of granulocyte-macrophage colony-stimulating factor.

  1998cited by this paper
• Origin, maturation and antigen presenting function of dendritic cells.

  1997cited by this paper
• Vaccination of patients with B–cell lymphoma using autologous antigen–pulsed dendritic cells

  1996cited by this paper

• Serum Oxidized LDL and Interleukin-10 as Biomarkers for Peripheral Artery Disease in Chronic Myeloid Leukemia Patients Receiving Tyrosine Kinase Inhibitor Therapy

  2026cites this paper
• Small molecule inhibitors as adjuvants in cancer immunotherapy: enhancing efficacy and overcoming resistance

  2024cites this paper
• Alterations in cellular metabolisms after TKI therapy for Philadelphia chromosome-positive leukemia in children: A review

  2022cites this paper
• RTK Inhibitors in Melanoma: From Bench to Bedside

  2021cites this paper
• Discovery of a highly potent kinase inhibitor capable of overcoming multiple imatinib-resistant ABL mutants for chronic myeloid leukemia (CML).

  2021cites this paper
• Novel Treatment Strategies Utilizing Immune Reactions against Chronic Myelogenous Leukemia Stem Cells

  2021cites this paper
• COVID-19 in persons with chronic myeloid leukaemia

  2020cites this paper
• Monocyte‐derived dendritic cells display a highly activated phenotype and altered function in patients with familial Mediterranean fever1

  2020cites this paper
• The Deubiquitinase Inhibitor b-AP15 and Its Effect on Phenotype and Function of Monocyte-Derived Dendritic Cells

  2019cites this paper